US Patent

US9283209 — Oral formulations of deferasirox

Composition of Matter · Assigned to Novartis AG · Expires 2034-11-21 · 9y remaining

Vulnerability score 4/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects orally administerable formulations of deferasirox that release the drug substance under specific pH conditions.

USPTO Abstract

Orally administerable deferasirox formulations are disclosed having reduced release under gastric conditions and fast release at near neutral pH or at neutral pH.

Drugs covered by this patent

Patent Metadata

Patent number
US9283209
Jurisdiction
US
Classification
Composition of Matter
Expires
2034-11-21
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.